Treatment of Heart Failure With Associated Functional Mitral Regurgitation Using the ARTO System Initial Results of the First-in-Human MAVERIC Trial (Mitral Valve Repair Clinical Trial) by Rogers, Jason H. et al.
J A C C : C A R D I O V A S C U L A R I N T E R V E N T I O N S VO L . 8 , N O . 8 , 2 0 1 5
ª 2 0 1 5 B Y T H E AM E R I C A N C O L L E G E O F C A R D I O L O G Y F O U N DA T I O N I S S N 1 9 3 6 - 8 7 9 8 / $ 3 6 . 0 0
P U B L I S H E D B Y E L S E V I E R I N C . h t t p : / / d x . d o i . o r g / 1 0 . 1 0 1 6 / j . j c i n . 2 0 1 5 . 0 4 . 0 1 2Treatment of Heart Failure With
Associated Functional Mitral
Regurgitation Using the ARTO System
Initial Results of the First-in-Human MAVERIC Trial
(Mitral Valve Repair Clinical Trial)Jason H. Rogers, MD,* Martyn Thomas, MD,yMarie-Claude Morice, MD,z Inga Narbute, MD,xMilana Zabunova, MD,x
Thomas Hovasse, MD,z Mathieu Poupineau, MD,k Ainars Rudzitis, MD,x Ginta Kamzola, MD,x Ligita Zvaigzne, MD,x
Samantha Greene, BA,{ Andrejs Erglis, MDxABSTRACTFro
St
Ce
Cla
Ms
of
MaOBJECTIVES MAVERIC (Mitral Valve Repair Clinical Trial) reports the safety and efﬁcacy of the ARTO system in patients
with symptomatic heart failure and functional mitral regurgitation (FMR).
BACKGROUND The ARTO system percutaneously modiﬁes the mitral annulus to improve leaﬂet coaptation in FMR.
METHODS The MAVERIC trial is a prospective, nonrandomized ﬁrst-in-human study. Key inclusion criteria were systolic
heart failure New York Heart Association functional classes II to IV, FMR grade $2þ, left ventricular (LV) ejection
fraction #40%, LV end-diastolic diameter >50 mm and #75 mm. Exclusion criteria were clinical variables that precluded
feasibility of the ARTO procedure. Primary outcomes were safety (30-day major adverse events) and efﬁcacy
(MR reduction, LV volumes, and functional status).
RESULTS Eleven patients received the ARTO system, and there were no procedural adverse events. From baseline
to 30 days, there were meaningful improvements. Effective regurgitant oriﬁce area decreased from 30.3  11.1 mm2
to 13.5  7.1 mm2 and regurgitant volumes from 45.4  15.0 ml to 19.5  10.2 ml. LV end-systolic volume index
improved from 77.5  24.3 ml/m2 to 68.5  21.4 ml/m2, and LV end-diastolic volume index 118.7  28.6 ml/m2 to
103.9  21.2 ml/m2. Mitral annular anteroposterior diameter decreased from 45.0  3.3 mm to 38.7  3.0 mm.
Functional status was 81.8% New York Heart Association functional class III/IV improving to 54.6% functional class I/II.
At 30 days, there were 2 adverse events: 1 pericardial effusion requiring surgical drainage; and 1 asymptomatic
device dislodgement.
CONCLUSIONS The ARTO system is a novel transcatheter device that can be used safely with meaningful efﬁcacy in the
treatment of FMR. (Mitral Valve Repair Clinical Trial [MAVERIC]; NCT02302872) (J Am Coll Cardiol Intv 2015;8:1095–104)
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ABBR EV I A T I ON S
AND ACRONYMS
AP = anteroposterior
CS = coronary sinus
CT = computed tomography
EROA = effective regurgitant
oriﬁce area
FMR = functional mitral
regurgitation
GCV = great cardiac vein
LA = left atrium
LV = left ventricle
MR = mitral regurgitation
TEE = transesophageal
echocardiographic
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1096results in restricted leaﬂet motion and inade-
quate leaﬂet coaptation (functional or sec-
ondary MR). Moderate-to-severe MR is
present in up to 74% of inpatients and 45%
of outpatients with systolic heart failure,
and the presence of FMR is associated with
a higher mortality rate than for patients
without FMR (1). Despite the use of
guideline-directed medical therapy for sys-
tolic heart failure, quality of life and survival
remain poor in patients with concomitant
FMR (2). Small randomized clinical trials of
patients with ischemic MR undergoing coro-
nary artery bypass surgery with and without
MR correction have shown improved LV
remodelling and functional capacity in theMR correction group (3,4). However, many patients
with moderate-to-severe FMR have signiﬁcant
comorbidities and are not routinely offered surgery
in clinical practice (5).
Percutaneous therapies have the potential to allow
treatment of FMR in patients who are not currently
offered surgery. Although other transcatheter tech-
nologies currently exist, there remain concerns with
technical complexity, safety, and efﬁcacy. The ARTO
(MVRx Inc., Belmont, California) system is a catheter-
based system designed to treat FMR. The mechanism
of the device consists of a suture that connects
interatrial-septal and coronary sinus anchors. This
suture is tensioned in order to shorten the ante-
roposterior (AP) diameter of the mitral annulus,
thereby improving mitral leaﬂet coaptation and
reducing FMR. We previously reported that this sys-
tem was effective in ameliorating FMR in an ovine
tachycardia model, and we subsequently performed
successful temporary transcatheter implantation in 2
patients before planned mitral valve surgery (6,7). In
this paper, we report the ﬁrst-in-human 30-day pri-
mary outcome measures of safety and efﬁcacy for 11
patients treated with the latest generation of the
ARTO device.
METHODS
Patients were enrolled at a single institution (Pauls
Stradins Clinical University Hospital, Riga, Latvia)
between October 2013 and May 2014. A local heart
team consisting of a cardiologist, cardiac surgeon,
and heart failure specialist evaluated all patients,
and they were deemed to be at high surgical risk
due to underlying comorbidities and would not be
offered surgery as part of routine clinical care.
All patients provided informed consent and the
MAVERIC (Mitral Valve Repair Clinical Trial)protocol was approved by the institutional ethics
committee.
Key inclusion criteria for the trial included the
following: age 21 to 85 years, inclusive; New York
Heart Association functional classes II to IV systolic
heart failure of any etiology; FMR grade $2þ; LV
ejection fraction #40%; LV end-diastolic diameter
>50 mm and #75 mm; and transseptal puncture
feasibility. Key exclusion criteria consisted of the
following: femoral or internal jugular vein unable to
accommodate a 16-F introducer sheath; structural
abnormality of the mitral valve (e.g., ﬂail, prolapse,
or leaﬂet calciﬁcation); signiﬁcant mitral annular
calciﬁcation; hemodynamic instability (systolic pres-
sure <90 mm Hg without afterload reduction,
cardiogenic shock, need for inotropic support or
intra-aortic balloon pump); previous mitral valve
surgery or valvuloplasty or any currently implanted
prosthetic valve or ventricular assist device; history
of rheumatic heart disease; any atrial septal defect or
patent foramen ovale associated with clinical symp-
toms; any atrial septal aneurysm; serum creatinine
>2.5 mg/dl or dialysis dependence; platelet count
<100  103 cells/mm3; any active infection, endo-
carditis, or intracardiac thrombus; percutaneous cor-
onary intervention or surgery anticipated within
the 6-month follow-up period following the investi-
gational procedure; life expectancy <1 year.
The primary safety outcome was the major
adverse event rate at 30 days post-procedure. Major
adverse events were deﬁned as stroke, myocardial
infarction, death, any device-related surgery, and
any events (even if unforeseen in the study plan-
ning) that the events committee might consider
major. The primary efﬁcacy outcome was FMR grade
and change from baseline to 30 days evaluated by
2-dimensional transthoracic echocardiogram. Other
evaluations obtained included functional status, left
ventricular volume and function indices, and proce-
dural details. Follow-up to 3 years post-procedure is
planned. Successful device placement was deﬁned as
successful delivery of the device including retrieval of
all catheters and no procedural device-related major
adverse events. Procedure time was deﬁned as the
time from ﬁrst guidewire introduction to last catheter
removal.
All echocardiographic and clinical data were
monitored and analyzed by an independent core
laboratory (Cardiovascular European Research
Centre, Massy, France). Echocardiographic grading of
MR severity at baseline and follow-up was performed
in accordance with current American Society of
Echocardiographic guidelines, and MR was graded on
a traditional 0 to 4þ scale (8). Because FMR differs
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1097from primary MR in that the parameters of effec-
tive regurgitant oriﬁce area (EROA) $20 mm2 and
regurgitant volume $30 ml identify signiﬁcant FMR
because of their prognostic value, these indices were
included in the results summary (9). Computed to-
mography (CT) scans were also performed at baseline
and in follow-up to assess for patency of the great
coronary sinus and device appearance.
PROCEDURE AND DEVICE DESCRIPTION. All 11 pro-
cedures were carried out by the same team of inter-
ventional cardiologists, imaging specialists, and
anesthesiologists. The procedures were carried out
under general anesthesia with transesophageal
echocardiographic (TEE) guidance. The procedure has
been described in detail previously (6,7). Brieﬂy, 1
interventionalist worked from the right internal
jugular vein using a 16-F sheath and the other from
the right femoral vein using a 16-F sheath. A magnetic
catheter (MagneCath, MVRx Inc.) was placed in the
coronary sinus (CS) from the right internal jugular
vein. A standard transseptal puncture in the anterior
mid-fossa was performed by the femoral operator
under TEE guidance and a second MagneCath was
placed in the left atrium (LA). The 2 MagneCaths were
manipulated and linked magnetically posteriorly in
the LA behind the posterior mitral leaﬂet. A small
puncturing wire was then advanced from the CS into
the LA MagneCath and externalized to create a
continuous loop wire from the right internal jugular
vein to the right femoral vein. Through a series of
wire and catheter exchanges, a 3-cm CS anchor
(T-Bar, MVRx Inc.) was then placed in the coronary
sinus and connected to an atrial septal anchor by a
suture of adjustable length. This suture was then
adjusted in length in order to shorten the AP diameter
of the mitral annulus until signiﬁcant reduction
was seen in the mitral regurgitation as assessed by
TEE. The suture was then “locked” and cut, allowing
removal of the delivery system via the femoral vein
and jugular vein. The procedure is illustrated in
Figure 1. A single loading dose of clopidogrel was
given on the day of the study procedure following
treatment, then 75-mg orally daily for a minimum of
3 months. Aspirin 75 to 100 mg was given daily post-
procedure at the investigator’s discretion for up to
6 months following the study procedure. Heparin was
given during the procedure to maintain a therapeutic
activated clotting time of 250 to 300 s.
STATISTICAL ANALYSIS. Continuous variables are
expressed as mean  SD. Statistical comparisons are
not reported due to the small number of patients in
this study. The authors had full access to the data
and take full responsibility for the integrity of thedata. All authors have read and agree to the manu-
script as written.
RESULTS
Eleven patients were enrolled and 10 had $3þ FMR
at enrolment, 1 had 2þ FMR, and all were symptom-
atic despite guideline-directed medical therapy.
Demographics and baseline characteristics of the
patients are shown in Table 1. Patients were pre-
dominantly male (80%) and had a mean age of
60 years. Despite the high surgical risk of these
patients as determined by a heart team, the logistic
EuroSCORE (European System for Cardiac Operative
Risk Evaluation) (6.5  4.6%) and Society of Thoracic
Surgeons score (5.0  3.7%) were intermediate, indi-
cating in a similar way to the transcatheter aortic
valve replacement population that this score does
not always adequately reﬂect the risk as assessed by a
heart team. Forty-six percent of patients had revas-
cularization before the procedure (27% percutaneous
coronary intervention and 18% coronary artery
bypass graft). These patients were symptomatic, with
81.8% being New York Heart Association functional
class III/IV, and there was a mean baseline B-type
natriuretic peptide level of 753.8 ng/l. No patient
had a biventricular pacemaker as none met the cur-
rent guideline recommendations for this therapy
based on QRS duration, ejection fraction, and pres-
ence of sinus rhythm (10). Procedural times shown in
Figure 2 favorably decreased during this ﬁrst-in-
human experience. A case example is shown in
Figure 3. Safety and efﬁcacy at 30 days are shown in
Tables 2 and 3 and Figure 4. No procedural safety
events occurred in any patient. At 30 days, MR
grade, LV volumes, mitral annular dimensions, and
functional status all improved. Pre-procedure FMR
was 90% grades 3 to 4þ, improving to 82% grades
1 to 2þ at 30 days. EROA by proximal isovelocity sur-
face area at baseline to 30 days decreased from
30.3  11.1 to 13.5  7.1 mm2, and regurgitant
volumes decreased from 45.4  15.0 to 19.5  10.2 ml.
LV end-systolic volume index decreased from
77.5  24.3 ml/m2 to 68.5  21.4 ml/m2 and LV end-
diastolic volume index from 118.7  28.6 ml/m2 to
103.9  21.2 ml/m2. Vena contracta improved from
6.2  1.4 mm at baseline to 3.0  1.1 mm at 30 days.
Mitral annular AP diameter decreased from 45.0 
3.3 mm to 38.7  3.0 mm. Functional status was
81.8% New York Heart Association functional class
III/IV and 18.2% functional class I/II at baseline
improving to 45.5% functional class III/IV and 54.6%
functional class I/II. Pulmonary artery systolic pres-
sures as determined by echocardiography improved
FIGURE 1 The ARTO System Implantation Procedure
(A) Great cardiac vein (GCV) and left atrial (LA) magnetic catheters (MagneCaths) in position and magnetically linked behind the P2 segment of
the posterior mitral leaﬂet. (B) Close-up of magnetically linked LA and GCV MagneCaths. Each magnetic catheter has a speciﬁc shape and
lumen to direct and receive the crossing wire. (C) The crossing wire (arrow) is pushed from the GCV into the LA MagneCath. The MagneCaths
are aligned to direct the wire safely from the GCV to the LA through the atrial wall. (D) After using an exchange catheter, the loop guidewire is
in place across the LA. This guidewire directs the placement of the GCV anchor (T-Bar) and septal anchor. (E) The ARTO System in place before
tensioning. T-Bar is indicated with a single arrow, and the septal anchor is indicated by a double arrow. (F) Tensioning of the bridge results in
precise shortening of the mitral annulus anteroposterior diameter (arrows) and elimination of functional mitral regurgitation. Once the ﬁnal
position is attained, the suture is cut and secured with a suture lock.
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1098from 44  14 mm Hg at baseline (n ¼ 8) to 34 
10 mm Hg at 30 days (n ¼ 9).
Antiplatelet therapy was recommended, but not
mandated, before and after the procedure at the treat-
ing physician’s discretion. Warfarin was not given un-
less the patient had another indication for
anticoagulation, such as atrial ﬁbrillation. The pre-
procedural anticoagulation was 18% (2 of 11) on
warfarin, 9% (1 of 11) on warfarin þ aspirin, 45% (5 of 11)
on single antiplatelet (aspirin or clopidogrel) therapy,
18% (2 of 11) on dual antiplatelet therapy, 1 with noantiplatelet or anticoagulant agent. Thepost-procedural
regimenwas 45% (5 of 11) onwarfarin alone, 45% (5 of 11)
on warfarin þ clopidogrel, 9% (1 of 11) on dual anti-
platelet therapy.
There were 2 adverse events in follow-up. In 1 sub-
ject, an asymptomatic posterior pericardial effusion
was noted 5 days after the procedure, which became
large by day 15 and was associated with dyspnea.
The patient was on warfarin post-procedure due to a
history of atrial ﬁbrillation. Attempts to percutane-
ously drain the effusion were not successful, and the
TABLE 1 Baseline Patient Demographics (N ¼ 11)
Age, yrs 60  11
Logistic EuroSCORE, % 6.5  4.6
STS score, % 5.0  3.7
HF hospitalizations in previous 2 yrs 1.1  0.7
Nonischemic HF etiology 54.5 (6)
Male 81.8 (9)
Hypertension 27.3 (3)
COPD 27.3 (3)
Previous PCI 27.3 (3)
Previous CABG 18.2 (2)
Atrial ﬁbrillation 81.8 (9)
Pacemaker/ICD 9.1 (1)
QRS duration, ms 117  19
Medical therapy
ACE inhibitor 63.6 (7)
Beta-blocker 90.9 (10)
Aldactone 81.8 (9)
Diuretic 72.7 (8)
Digoxin 45.5 (5)
NYHA functional class
I 0
II 18.2 (2)
III 72.7 (8)
IV 9.1 (1)
LVEF, % 37.5  7.7
Total contrast used, cc (n ¼ 10) 121.7  85.6
Total procedure time, min 104.8  29.6
Values are mean  SD or % (n).
ACE ¼ angiotensin-converting enzyme; CABG ¼ coronary artery bypass graft;
COPD ¼ chronic obstructive pulmonary disease; EuroSCORE ¼ European System
for Cardiac Operative Risk Evaluation; HF ¼ heart failure; ICD ¼ implantable
cardioverter-deﬁbrillator; LVEF ¼ left ventricular ejection fraction; NYHA ¼ New
York Heart Association; PCI ¼ percutaneous coronary intervention; STS ¼ Society
of Thoracic Surgeons.
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1099patient underwent successful surgical drainage of
the effusion by a subxiphoid approach without
recurrence. In another patient, the CS T-Bar was
found to have dislocated from the great cardiac vein
(GCV) into the left atrium. This dislocation was
asymptomatic and detected on routine follow-up CT
scan performed on day 35 post-procedure. TEE
showed no defect or shunt from the LA to CS. The
patient underwent successful elective surgical mitral
valve replacement on post-procedure day 65—all
tissue in the LA was well healed with no evidence of
erosion or damage. All other 9 subjects had no
adverse events at 30 days, and CT scans showed the
device to be intact and the CS patent in these
subjects.
DISCUSSION
This ﬁrst-in-human study has demonstrated that the
ARTO transcatheter mitral valve repair system can besafely placed in high-risk patients with systolic heart
failure and FMR. These patients were symptomatic
despite guideline-directed medical therapy and
revascularization where appropriate. The procedure
has a favorable learning curve in this small series and
is performed primarily with ﬂuoroscopic guidance.
There were no procedural adverse events. The pro-
cedure is performed entirely at the atrial level;
therefore, patients remain hemodynamically stable
and there is no tendency for ventricular arrhythmias.
No conduction disturbances were seen in this series.
Although the true efﬁcacy of the device will be
proven during longer-term follow-up, there was
markedly reduced FMR at 30 days. All echocardio-
graphic measures of FMR including American Society
of Echocardiographic grade, regurgitant volume, vena
contracta, and EROA showed a meaningful immediate
improvement at the conclusion of the procedure and
at 1-month follow-up. This is in contrast to other CS
devices where efﬁcacy may not be seen acutely, but
only after time (11).
The ARTO procedure is more similar in concept to
indirect annuloplasty than to direct annuloplasty as
there are no anchor elements directly attached to the
mitral annulus. It is known that the CS travels on
average 5 to 10 mm above the plane of the mitral
annulus (12). The movement of the mitral annulus in
the ARTO procedure occurs by distraction of tissue in
the atrium above the annulus, which is then trans-
mitted to annular tissue. In general, the transseptal
puncture was targeted more anteriorly in a low-to-
middle location in the fossa ovalis to allow a more
horizontal and AP suture vector. Although the suture
angle is not parallel to the true AP diameter of the
mitral annulus, it does exert a force vector in the AP
direction that results in shortening of the AP diam-
eter. The angle of the suture is w20 to 30 posterior
to a true AP orientation. The details of this force
vector have been previously published (7). The de-
gree of AP diameter reduction achieved with the
ARTO device is more than reported with any other
indirect transcatheter annuloplasty approach to date.
There was some minor loss of efﬁcacy between the
post-procedure and 30-day values for MR quantiﬁ-
cation. As there are no major structural changes seen
with the device at 30 days, the mechanism is likely
related to tissue remodeling around the device and to
the small number of patients treated in this series.
The system should not develop slack because the
septal and coronary sinus anchors are rigid and the
suture material and lock are inelastic.
The 2 adverse events between days 1 and 30 may be
mitigated in the future. The posterior pericardial
effusion is likely to have been caused by guidewire
FIGURE 2 Procedural Learning Curve
Procedural times (minutes) favorably decrease during this ﬁrst-in-human experience.
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1100manipulation within the LA, possibly causing a very
small perforation of the LA appendage. An angled
guidewire was used in this series to help direct the LA
MagneCath, and in future procedures, a J-tipped wire
will be used. Increased operator experience and the
use of a deﬂectable guide catheter may also minimize
this complication in the future. Migration of the cor-
onary sinus T-Bar anchor into the LA is a potential
complication of this procedure. This occurred
asymptomatically in 1 patient with no immediate
clinical sequelae. The mechanism of migration may
be related to the fact that the T-Bar has a shorter rigid
central portion and ﬂexible ends. This problem may
be minimized in the future by avoiding excess tension
on the atrial/CS wall during delivery. The required
tension placed on the suture has been measured
experimentally in an ovine model to be w147 g (7).
The tension placed on the suture in a human is likely
greater, but it is difﬁcult to quantify. Theoretically,
increased tension could result in device migration,
but in this series, all patients were tensioned to a
similar degree. Therefore, correlating the degree of
tension with risk in this series is not possible. No
occurrence of compression of the circumﬂex coronary
artery was seen in this study. Coronary artery
compression (which has been observed with other CS
devices) was avoided with the ARTO device in 2 ways.
First, careful pre-procedural CT scan can demonstrate
the 3-dimensional relationship between the coronarysinus and the circumﬂex coronary artery, allowing
some pre-procedural planning with regard to place-
ment of the CS anchor, although no patient was
excluded pre-procedure for concern of coronary
compression. Second, as the suture is tensioned at
the end of this procedure, a simultaneous coronary
angiogram is performed to exclude coronary artery
compression. If at any point, coronary artery com-
pression or other untoward effect is seen, the entire
device can be removed before ﬁnal deployment and
the procedure discontinued, although this was not
necessary in this series.
Previous pathophysiological studies have demon-
strated that an increase in AP mitral annular diameter
is the common ﬁnal pathway in the development of
FMR (13), and that shortening this dimension is crit-
ical to alleviating MR. The surgical approach to FMR
generally involves placement of a rigid circumferen-
tial annuloplasty ring directly on the mitral annulus
with a goal of reduction in mitral annular AP diameter
of at least 20% (14). A number of predictors for
recurrent MR after restrictive annuloplasty have been
identiﬁed, including LV end-diastolic diameter >65
mm (15), posterior leaﬂet angle $45 (16), and mitral
valve coaptation depth $11 mm (17). The effect of
these parameters on the success of percutaneous
therapies is yet to be elucidated. Of note, the ARTO
system achieves a 14% reduction in AP diameter at
30 days in this trial, which far exceeds that achieved by
FIGURE 3 ARTO Case Example
(A) Baseline 4-chamber transthoracic echocardiogram (TTE) showing nonischemic dilated left ventricle with leaﬂet tethering and annular
dilation. (B) The 4-chamber TTE color Doppler showing severe functional mitral regurgitation (Nyquist limit 64.0 cm/s). (C) LA and GCV
MagneCaths magnetically linked with crossing wire having passed from the GCV into the LA MagneCath (arrow). (D) Final angiographic
appearance of the ARTO System after tensioning and suture lock. The GCV anchor (T-Bar) in indicated by the single arrow and the septal anchor
by the double arrow. Note patent circumﬂex coronary artery seen with simultaneous left coronary artery injection. (E) Final 4-chamber TTE
image with atrial annular shortening. Suture bridge is indicated by the single arrow and the septal anchor by the double arrow. (F) Final 4-
chamber TTE color Doppler showing trace mild functional mitral regurgitation and improved leaﬂet coaptation (Nyquist limit 61.4 cm/s).
Abbreviations as in Figure 1.
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TABLE 2 Procedural Safety* up to 30 Days
Event Timing
Immediate
Procedural Events
(#72 h)
(n ¼ 11)
Post-Procedural
Events
(72 h to 30 Days)
(n ¼ 11)
Death 0 0
Stroke/TIA 0 0
Myocardial infarction 0 0
Mitral operation/intervention 0 1†
Bleeding complications 0 0
Acute kidney injury/renal failure‡ 0 0
Cardiac tamponade 0 1
Vascular access site–related complication 0 0
Conduction disturbances 0 0
*As adapted from the VARC-2 (Valve Academic Research Consortium 2) guidelines (20).
†Asymptomatic T-Bar dislodgement noted at day 35, elective surgical mitral valve replacement at
day 65. ‡Acute kidney injury (up to 7 days); renal failure >7 and #30 days.
TIA ¼ transient ischemic attack.
TABLE 3 Efﬁcacy to 30 Days (n ¼ 11)
Baseline Post Procedure 30 Days
Mitral regurgitation by ASE
1 0 (0) 6 (55) 6 (55)
2 1 (9) 4 (36) 3 (27)
3 5 (45) 1 (9) 2 (18)
4 5 (45) 0 (0) 0 (0)
LVEF, % 37.5  7.7 35.9  8.9 35.2  8.7
LVESVi, ml/m2 77.5  24.3 72.1  22.5 68.5  21.4
LVEDVi, ml/m2 118.7  28.6 110.6  24.5 103.9  21.2
AP annulus diameter, mm 45.0  3.3 37.8  2.3 38.7  3.0
Tenting
Area, cm2 2.3  0.5 1.4  0.4 1.5  0.4
Height, mm 8.7  2.2 5.9  1.4 6.3  1.3
Regurgitant volume/EROA by PISA n ¼ 9 n ¼ 7 n ¼ 8
EROA, mm2 30.3  11.1 10.9  5.3 13.5  7.1
RV, ml 45.4  15 15.4  7.6 19.5  10.2
Paired data
EROA, mm2 (n ¼ 6) 29.8  9.2 ND 11.8  6.8
RV, ml (n ¼ 8) 44.7  10.8 ND 17.0  8.8
Regurgitant volume by LV volume method n ¼ 10 n ¼ 10 n ¼ 9
RV, ml 38.2  12.1 17.1  11.0 16.4  9.7
Paired data
RV, ml (n ¼ 9) 38.9  12.8 ND 16.4  8.1
Vena contracta, mm 6.2  1.4 2.8  0.5 3.0  1.1
6-min walk test, m (n ¼ 9)* 401.3  60 ND 415.7  46.5
NYHA functional class
I 0 0 0
II 18.2 54.6 54.6
III 72.7 45.5 45.5
IV 9.1 0 0
Values are n (%), mean  SD, or %. See Study Limitations section for details on numbers of echocardiographic
follow-up. *Two patients unable to walk at all.
AP ¼ anteroposterior; ASE ¼ American Society of Echocardiography; EROA ¼ effective regurgitant oriﬁce area;
LV ¼ left ventricle; LVEDVi ¼ left ventricular end-diastolic volume index; LVESVi ¼ left ventricular end-systolic
volume index; ND ¼ not determined; PISA ¼ proximal isovelocity surface area; RV ¼ regurgitant volume; other
abbreviations as in Table 1.
Rogers et al. J A C C : C A R D I O V A S C U L A R I N T E R V E N T I O N S V O L . 8 , N O . 8 , 2 0 1 5
MAVERIC Trial J U L Y 2 0 1 5 : 1 0 9 5 – 1 0 4
1102other currently available CS-based indirect annulo-
plasty devices. Although no patients in this series
required cardiac resynchronization therapy, we do not
believe that a CS lead would preclude performance of
the ARTO procedure, because CS leads are small (4-F to
6-F) and the CS diameter in heart failure patients is
large. Other percutaneous techniques for the treat-
ment of FMR include edge-to-edge repair with the
MitraClip (Abbott, Menlo Park, California). This device
has been applied successfully to FMR in the setting of
end-stage systolic heart failure, but it does not result in
a meaningful reduction of mitral annular diameter,
which may lead to decreased durability over time,
especially in patients with very large annuli or ven-
tricles (18). Despite the potential advantages of a direct
annular approach, the development and adoption of
percutaneous direct annuloplasty has lagged behind
other approaches, largely owing to the technical chal-
lenges of catheter delivery and positioning. Much
discussion has taken place recently on the relative
merits of transcatheter mitral valve repair versus
replacement and the reduction of MR (as generally
achieved by transcatheter repair) as comparedwith the
elimination of MR (as aimed for with transcatheter
replacement). Although a surgical trial of repair versus
replacement demonstrated equipoise between the 2
therapies in mid-term follow-up (19), the decision of
transcatheter repair versus replacement may well
depend on patient clinical characteristics and the
relative risk of the procedure. The current trans-
catheter replacement devices appear to carry a high
procedural risk, and it is likely that the procedural risk
will be higher with replacement than repair for some
time to come. The patients in this series treated with
the ARTO device were at high risk with a mean LV
ejection fraction of 37.5%, and all had been turned
down for cardiac surgery. This group may therefore
be particularly suited to transcatheter repair. The
reduction in FMR in this series appears favorable
compared with that reported with other transcatheter
repair devices. Importantly, for FMR, an EROA
$20 mm2 and regurgitant volume $30 ml has been
shown to correlate with worse clinical outcomes, and
themean EROA (13.5 7.1 mm2) and RV (19.5 10.2 ml)
achieved in this series was well below these target
values (9).
STUDY LIMITATIONS. This is a small, nonran-
domized, nonblinded observational study. Because
of the innovative nature of the technology and
some variability in echocardiographic windows,
echocardiographic parameters were not measurable
in every patient at every time point. However, paired
interpretable data were used for comparisons, and all
echocardiographic assessments were performed by an
FIGURE 4 Efﬁcacy of ARTO System
(A) Mitral regurgitation grade at baseline, discharge, and 30-day follow-up. (B) New York Heart Association (NYHA) functional class at
baseline, discharge, and 30-day follow-up. (C) Anterior-posterior mitral annular dimension (mm) as measured on the parasternal long-axis
transthoracic echocardiographic view at baseline, discharge, and 30-day follow-up.
J A C C : C A R D I O V A S C U L A R I N T E R V E N T I O N S V O L . 8 , N O . 8 , 2 0 1 5 Rogers et al.
J U L Y 2 0 1 5 : 1 0 9 5 – 1 0 4 MAVERIC Trial
1103
PERSPECTIVES
WHAT IS KNOWN? Patients with systolic heart
failure often have coexistent FMR.
WHAT IS NEW? Although surgical correction of FMR
has been shown in some studies to improve quality of
life and reduce LV size, surgery is not routinely per-
formed in clinical practice because of patient comor-
bidities and perceived surgical risk. Consequently,
there is signiﬁcant interest in developing minimally
invasive transcatheter methods of correcting FMR. In
this study, we safely treated 11 patients with the novel
ARTO system, with meaningful reductions in FMR and
improved functional status.
WHAT IS NEXT? Further investigations with larger
randomized trials addressing the impact of trans-
catheter FMR correction as compared with medical
or surgical therapy are needed.
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1104independent core lab. Given the small numbers in this
study, the strength of any statistical comparison is
limited and therefore not reported.
CONCLUSIONS
This ﬁrst-in-human study of the ARTO transcatheter
mitral valve repair system demonstrates that the
procedure can be safely performed with a favorable
learning curve. There is strong evidence of device
efﬁcacy with clinically meaningful reductions in MR.
These initial data are extremely promising, especially
in terms of safety, and larger studies with longer-term
follow-up are planned to conﬁrm sustained reduction
of MR and improvement in functional status of the
patients.
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